Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 34 Issue 5, May 2016

Artist's representation of individuals (highlighted in green) who remain healthy despite carrying mutations that cause severe Mendelian diseases. Chen et al. analyze genetic data from over half a million people and identify 13 healthy individuals who harbor highly penetrant disease-causing mutations. No study participants are depicted (p 531). Image credit: Marina Spence; images provided by John Ambrose

Volume 34 Issue 5

Subscribe

Editorial

  • A House panel's witch hunt against fetal tissue research demands a forceful response from the biomedical community.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Skeletal muscle atrophy offers a huge opportunity for an effective drug. After many failures, industry may be on the verge. Ken Garber reports.

    • Ken Garber
    News Feature
Top of page ⤴

Bioentrepreneur

Top of page ⤴

Correspondence

Top of page ⤴

Feature

  • Immuno-oncology was hotly pursued by investors in 2015, along with drug delivery platforms. In the agbiotech world, a systems biology company set up shop.

    • Aaron Bouchie
    • Laura DeFrancesco
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • Individuals who remain healthy despite carrying a disease-causing mutation are identified in an analysis of over a half million people.

    • Daniel MacArthur
    News & Views

  • Autoimmune diseases are reversed in mice using nanoparticles that display disease-associated antigens bound to MHC class II molecules.

    • Rafael M Rezende
    • Howard L Weiner
    News & Views
Top of page ⤴

Perspective

  • A long-held goal in sequencing has been to use a voltage-biased nanoscale pore in a membrane to measure the passage of a linear, single-stranded (ss) DNA or RNA molecule through that pore. With the development of enzyme-based methods that ratchet polynucleotides through the nanopore, nucleobase-by-nucleobase, measurements of changes in the current through the pore can now be decoded into a DNA sequence using an algorithm. In this Historical Perspective, we describe the key steps in nanopore strand-sequencing, from its earliest conceptualization more than 25 years ago to its recent commercialization and application.

    • David Deamer
    • Mark Akeson
    • Daniel Branton
    Perspective
Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Resource

Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Advanced search

Quick links